ATS 2021, News
Oral Corticosteroid Dose Management With Impaired Adrenal Function Evaluated
Patients with normal adrenal function are largely able to eliminate the use of oral corticosteroids or achieve a daily dose of 5 mg or less.
Your search for oral corticosteroids returned 22 results
AAAAI 2021, News
Benralizumab May Reduce or Eliminate Oral Corticosteroid Use in Severe Asthma
Patients with asthma who depend on oral corticosteroids (OCS) may be able to reduce the dependence or eliminate the use of OCS altogether with benralizumab.
CHEST 2021, News
Dupilumab Improves Severe Asthma Outcomes, Regardless of Baseline OCS Dose
A post-hoc analysis of the VENTURE trial evaluated whether baseline oral corticosteroid dosage affected the efficacy of dupilumab in improving severe asthma outcomes.
ATS 2021, News
Dupilumab Effective in Treating OCS-Dependent Asthma, Weaning OCS Use
Long-term treatment of oral corticosteroid (OCS)-dependent asthma with dupilumab has shown efficacy in weaning off OCS while improving lung function.
News
Zolgensma Labeling Updated With Additional Safety Information
Zolgensma is an adeno-associated virus vector-based gene therapy.
Drugs in the Pipeline
Dupilumab Under Review for Pediatric Asthma
The submission was based on data from the double-blind, placebo-controlled VOYAGE trial.
Drugs in the Pipeline
Tezepelumab BLA Submitted for Severe Asthma
The BLA submission is supported by data from the PATHFINDER clinical program.
AAAAI 2021, News
Active Eosinophilic Esophagitis Associated With Increased Asthma Severity
Active eosinophilic esophagitis appears to be associated with lower lung function and increased asthma severity in children with comorbid asthma.
CHEST 2021, News
Tezepelumab Improves Lung Function in Severe, Uncontrolled Asthma
NAVIGATOR trial results presented at CHEST 2021 show the effect of tezepelumab on peak expiratory flow rates in severe asthma.
News
Tezepelumab Gets Priority Review for Severe Asthma
The BLA submission included data from the pivotal phase 3 NAVIGATOR trial that assessed tezepelumab in 1061 patients with severe, uncontrolled asthma.
